Pyridine and pyrimidine derivatives

Patent metadata

Field	Value
Publication number	US-11352369-B2
Application number	US-202016931786-A
Country	US
Kind code	B2
Filing date	Jul 17, 2020
Priority date	Jun 29, 2015
Publication date	Jun 7, 2022
Grant date	Jun 7, 2022

Abstract

Provided are a series of novel pyridine or pyrimidine derivatives which inhibit CDK9 and may be useful for the treatment of hyperproliferative diseases. In particular the compounds are of use in the treatment of proliferative disease such as cancer including hematological malignancies such as acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, diffuse large B cell lymphoma, Burkitt's lymphoma, follicular lymphoma and solid tumors such as breast cancer, lung cancer, neuroblastoma and colon cancer.

First claim

What is claimed is:

1. A compound of Formula I:

wherein:
A is C(R 5 ) or N;
R 5 is H, C 1-3 alkyl, CN or halogen;
R 2 is 3-7 membered heterocycloalkyl or 3-7 membered cycloalkyl;
optionally substituted with one to three substituents independently selected from the group consisting of R 10 , OR 10 , SR 10 , S(O)R 10 , S(O) 2 R 10 , C(O)R 10 , C(O)OR 10 , OC(O)R 10 , OC(O)OR 10 , NH 2 , NHR 10 , N(R 10 ) 2 , NHC(O)H, NHC(O)R 10 , NR 10 C(O)H, NR 10 C(O)R 10 , (NHS(O) 2 R 10 , NR 10 S(O) 2 R 10 , NHC(O)OR 10 , NR 10 C(O)OR 10 , NHC(O)NH 2 , NHC(O)NHR 10 , NHC(O)N(R 10 ) 2 , NR 10 C(O)NH 2 , NR 10 C(O)NHR 10 , NR 10 C(O)N(R 10 ) 2 , C(O)NH 2 , C(O)NHR 10 , C(O)N(R 10 ) 2 , C(O)NHOH, C(O)NHOR 10 , C(O)NHS(O) 2 R 10 , C(O)NR 10 S(O) 2 R 10 , S(O) 2 NH 2 , S(O) 2 NHR 10 , S(O) 2 N(R 10 ) 2 , S(O) 2 NHC(O)OR 10 , S(O) 2 NR 10 C(O)OR 10 , C(O)H, C(O)OH, OH, CN, NO 2 , F, Cl, Br and I; wherein one or more ring CH 2 groups can optionally be replaced by a corresponding number of —C(O) groups, and one or more ring sulfur or nitrogen atoms may be optionally oxidized to form S-oxides or N-oxides;
R 10 , at each occurrence, is independently selected from the group consisting of a 3 to 6 membered cycloalkyl or heterocycloalkyl group, C 1-6 alkyl, —O—C 1-6 alkyl, C 1-6 alkyl-O—C 1-6 alkyl, NH 2 , C(O)NH 2 , C(O)H, C(O)OH, OH, CN, NO 2 , F, Cl, Br and I; wherein two R 10 groups together with the atoms to which they are attached may form a 3 to 6 membered cycloalkyl or heterocycloalkyl group; and each aforementioned R 10 alkyl, cycloalkyl and heterocycloalkyl group may be further substituted with one or two substituents independently selected from CN, OH, halogen, C 1-3 alkyl, —O—C 1-3 alkyl, NH 2 , NH—C 1-3 alkyl, and NHC(O)—C 1-3 alkyl;
R 4 is

wherein X and Y together with the atoms to which they are attached, form a 5 to 7 membered heterocycloalkyl ring which, in addition to the bridge nitrogen, may contain one or two heteroatoms selected from N, O, and S, which ring may be saturated or partially saturated;
wherein one or two ring CH 2 groups can optionally be replaced by a corresponding number of —C(O) groups, one or more ring sulfur or nitrogen atoms may be optionally oxidized to form S-oxides or N-oxides and wherein the ring may be substituted on a ring carbon by one or two R 10 substituents or on a ring nitrogen by an R 12 substituent;
J is N or CR 11 ; and
R 11 is H, or C 1-3 alkyl;
R 12 is at each occurrence independently selected from the group consisting of a 3 to 6 membered cycloalkyl or heterocycloalkyl group, C 1-6 alkyl, C 1-6 alkyl-O—C 1-6 alkyl, C(O)NH 2 , or C(O)H;
wherein R 12 alkyl, cycloalkyl and heterocycloalkyl group may be further substituted with one or two substituents independently selected from CN, OH, and halogen, C 1-3 alkyl, NH 2 , and NH—C 1-3 alkyl, NHC(O)—C 1-3 alkyl;
or pharmaceutical acceptable salts thereof.

2. The compound of claim 1 wherein A is C(R 5 ).

3. The compound of claim 2 wherein R 5 is chloro or fluoro.

4. The compound of claim 1 wherein R 2 is 3-7 membered cycloalkyl substituted with NHCOR 10 or R 10 .

5. The compound of claim 4 wherein R 2 is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.

6. The compound of claim 5 wherein R 2 is selected from cyclopentyl and cyclohexyl.

7. The compound of claim 6 wherein R 2 is cyclohexyl substituted with NHCOR 10 .

8. The compound of claim 1 wherein R 4 is

9. The compound of claim 8 wherein J is C(R 11 ).

10. The compound of claim 9 wherein R 11 is H.

11. The compound of claim 1 wherein X and Y together with the atoms to which they are attached form a 5 membered heterocycloalkyl ring.

12. The compound of claim 11 wherein X and Y together with the atoms to which they are attached form a 5 membered heterocycloalkyl ring in which one CH 2 is substituted with two methyl groups.

13. The compound of claim 1 wherein
A is C(R 5 );
R 5 is halogen;
R 2 is 3-7 membered cycloalkyl;
R 4 is

and
X and Y together with the atoms to which they are attached form a 5 membered heterocycloalkyl ring.

14. The compound of claim 1 wherein
A is C(R 5 );
R 5 is halogen;
R 2 is cyclohexyl;
R 4 is

and
X and Y together with the atoms to which they are attached form a 5 membered heterocycloalkyl ring.

15. The compound of claim 14 wherein
A is C(R 5 );
R 5 is chloro;
R 2 is cyclohexyl;
R 4 is

and
X and Y together with the atoms to which they are attached form a 5 membered heterocycloalkyl ring.

16. The compound of claim 1 wherein
A is C(R 5 );
R 5 is chloro;
R 2 is cyclohexyl substituted with NHC(O)R 10 ;
R 4 is

and
X and Y together with the atoms to which they are attached form a 5 membered heterocycloalkyl ring.

17. The compound of claim 1 wherein
A is C(R 5 );
R 5 is chloro;
R 2 is cyclohexyl substituted with NHC(O)R 10 ;
R 10 is C 1-6 alkyl;

R 4 is
J is C(R 11 ) and R 11 is H; and
X and Y together with the atoms to which they are attached form a 5 membered heterocycloalkyl ring.

18. The compound of claim 1 wherein
A is C(R 5 );
R 5 is chloro;
R 2 is cyclohexyl substituted with NHC(O)R 10 ;
R 10 is C 1-6 alkyl;
R 4 is

J is C(R 11 ) and R 11 is H; and
X and Y together with the atoms to which they are attached form a pyrrolidinyl wherein one CH 2 is substituted with two methyl groups.

19. A pharmaceutical composition containing a compound of claim 1 and at least one pharmaceutically acceptable carrier, diluent, or excipient.

Assignees

• Astrazeneca Ab

Inventors

• Barlaam Bernard
• De Savi Christopher
• Hawkins Janet
• Hird Alexander
• Lamb Michelle
• Pike Kurt
• Vasbinder Melissa

Classifications

• C07D498/04 Primary

  Ortho-condensed systems · CPC title

• C07D487/04

  Ortho-condensed systems · CPC title

• C07B2200/13

  Crystalline forms, e.g. polymorphs · CPC title

• C07D471/04 Primary

  Ortho-condensed systems · CPC title

• A61P35/00 Primary

  Antineoplastic agents · CPC title